Peer-reviewed veterinary case report
Using human erythropoietin to treat anemia in dogs and cats
By Cowgill, L D et al.·Published in Journal of the American Veterinary Medical Association·1998·Department of Medicine and Epidemiology, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure.
Plain-English summary
A group of dogs and cats with chronic kidney disease were treated with a medication called recombinant human erythropoietin (r-HuEPO) to help manage their anemia, a common issue in these pets. The treatment increased their red blood cell counts and improved their overall well-being, including appetite and energy levels. However, some pets experienced side effects like seizures and high blood pressure. While r-HuEPO showed promise in helping these animals, it also carries risks that need careful consideration by veterinarians.
People also search for: dog anemia treatment · cat kidney disease symptoms · r-HuEPO for dogs and cats · chronic renal failure in pets · side effects of erythropoietin in dogs
Abstract
OBJECTIVE: To test efficacy and safety of recombinant human erythropoietin (r-HuEPO) administration in dogs and cats with naturally developing chronic renal failure. DESIGN: Case series. ANIMALS: 6 client-owned dogs and 11 client-owned cats with chronic renal failure. PROCEDURES: r-HuEPO was administered intravenously or subcutaneously. Erythropoietic effects were monitored by determining CBC, performing cytologic examination of bone marrow aspirates, and measuring serum iron concentration before and during treatment. Development of adverse effects was monitored by performing sequential clinical assessments, CBC, and serum biochemical tests and by measuring indirect blood pressure and anti-r-HuEPO antibody titers. RESULTS: Administration of r-HuEPO increased RBC and reticulocyte counts, hemoglobin concentration, and Hct comparably in dogs and cats. Assessments of clinical well-being, including appetite, energy, weight gain, alertness, strength, and playfulness, were improved variably. Adverse effects, including anemia, anti-r-HuEPO antibody production, seizures, systemic hypertension, and iron deficiency, were demonstrated inconsistently in dogs and cats. CLINICAL IMPLICATIONS: Anemia contributes to clinical manifestations of chronic renal failure in dogs and cats. Administration of r-HuEPO has the potential to resolve anemia and improve clinical well-being. However, its administration poses risks of antibody production and adverse effects associated with correction of RBC mass. Use of r-HuEPO in dogs and cats requires conscientious assessment of risks and benefits until homologous forms of erythropoietin are available.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/9491159/